GoAI
Get started
Ascendis Pharma A/S logo

Ascendis Pharma A/S

ASND

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$253.29

−$1.52 · -0.60%

Aug 21, 4:00 PM ET

ASND company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

65

Undervalued

Momentum

61

Gaining

Sentiment

63

Bullish

Risk resilience

71

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

Industry
Biotechnology
Sector
Healthcare
Headquarters
DK
CEO
Jan Moller Mikkelsen
Listed since
Jan 28, 2015
Employees
1,189

Market position

Day range

Current $253.29

52-week range

Current $253.29

Open
$253.62
Previous close
$254.81
Volume
363.77K
0.52× average
Average volume
694.48K
Average daily volume
Market cap
15.73B USD
Beta
0.38
Market reference 1
50-day average
$252.2
+0.43% above average
200-day average
$229.7
+10.27% above average

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score
9.4
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends677%-1681%-4040%-6398%Gross margin, FY2021: 54.71%Gross margin, FY2022: 76.28%Gross margin, FY2023: 83.36%Gross margin, FY2024: 87.83%Gross margin, FY2025: 85.08%Operating margin, FY2021: -5808.59%Operating margin, FY2022: -1097.85%Operating margin, FY2023: -170.79%Operating margin, FY2024: -76.66%Operating margin, FY2025: -18.92%Net margin, FY2021: -4931.56%Net margin, FY2022: -1139.63%Net margin, FY2023: -180.51%Net margin, FY2024: -103.97%Net margin, FY2025: -31.67%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 54.71%. Gross margin FY2022 76.28%. Gross margin FY2023 83.36%. Gross margin FY2024 87.83%. Gross margin FY2025 85.08%. Operating margin FY2021 -5808.59%. Operating margin FY2022 -1097.85%. Operating margin FY2023 -170.79%. Operating margin FY2024 -76.66%. Operating margin FY2025 -18.92%. Net margin FY2021 -4931.56%. Net margin FY2022 -1139.63%. Net margin FY2023 -180.51%. Net margin FY2024 -103.97%. Net margin FY2025 -31.67%.

Income trends

Revenue

691.71M EUR+90.22%

Operating income

−130.89M EUR+53.05%

Net income

−219.03M EUR+42.07%
Income trends across reported periods819.2M EUR309.24M EUR−200.72M EUR−710.68M EURRevenue, FY2021: 7.78M EURRevenue, FY2022: 51.17M EURRevenue, FY2023: 266.72M EURRevenue, FY2024: 363.64M EURRevenue, FY2025: 691.71M EUROperating income, FY2021: −451.79M EUROperating income, FY2022: −561.81M EUROperating income, FY2023: −455.54M EUROperating income, FY2024: −278.76M EUROperating income, FY2025: −130.89M EURNet income, FY2021: −383.58M EURNet income, FY2022: −583.19M EURNet income, FY2023: −481.45M EURNet income, FY2024: −378.08M EURNet income, FY2025: −219.03M EURFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 7.78M EUR. Revenue FY2022 51.17M EUR. Revenue FY2023 266.72M EUR. Revenue FY2024 363.64M EUR. Revenue FY2025 691.71M EUR. Operating income FY2021 −451.79M EUR. Operating income FY2022 −561.81M EUR. Operating income FY2023 −455.54M EUR. Operating income FY2024 −278.76M EUR. Operating income FY2025 −130.89M EUR. Net income FY2021 −383.58M EUR. Net income FY2022 −583.19M EUR. Net income FY2023 −481.45M EUR. Net income FY2024 −378.08M EUR. Net income FY2025 −219.03M EUR.
Metric (EUR)FY2025FY2024FY2023FY2022FY2021
Revenue691.71M EUR363.64M EUR266.72M EUR51.17M EUR7.78M EUR
Cost of goods sold103.18M EUR44.26M EUR44.4M EUR12.14M EUR3.52M EUR
Gross profit588.53M EUR319.38M EUR222.32M EUR39.04M EUR4.26M EUR
Research and development283.5M EUR307M EUR413.45M EUR379.62M EUR295.87M EUR
Selling, general, and administrative435.92M EUR284.55M EUR258.79M EUR215.85M EUR160.18M EUR
Operating expenses719.42M EUR598.15M EUR677.86M EUR600.85M EUR456.05M EUR
Interest income14.7M EUR14.36M EUR16.86M EUR7.43M EUR692K EUR
Interest expense77.46M EUR65.5M EUR44.07M EUR30.68M EUR3.91M EUR
Depreciation and amortization17M EUR17.71M EUR18.91M EUR17.51M EUR15.39M EUR
Operating income−130.89M EUR−278.76M EUR−455.54M EUR−561.81M EUR−451.79M EUR
Net income−219.03M EUR−378.08M EUR−481.45M EUR−583.19M EUR−383.58M EUR

Company facts updated Aug 24, 2026.

ASND peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research ASND

research.disclaimer